AVBCC recognizes Iovance Biotherapeutics' Dr. Fred Vogt with inaugural Global Cancer Research & Innovation Award. AVBCC has presented its Global Cancer Research & Innovation Award to Fred Vogt, PhD, JD, Interim CEO, President, and General Counsel, Iovance Biotherapeutics. Dr. Vogt's extraordinary blend of scientific leadership, strategic vision, and unwavering commitment to advancing breakthrough therapies embodies the spirit of innovation and impact this award honors." - Burt Zweigenhaft, PhD, DLitt NEW YORK, NY, UNITED STATES, October 6, 2026 / EINPresswire.com / - The Association for Value-Based Cancer Care (AVBCC) is pleased to announce Fred Vogt, PhD, JD, Interim CEO, President, and General Counsel, Iovance Biotherapeutics, as the recipient of its inaugural Global Cancer Research & Innovation Award. Presented to Dr. Vogt today at AVBCC's 2nd Annual Global Cancer Research & Innovation Symposium (GCRIS), this award recognizes his visionary leadership and contributions to advancing innovation in oncology. Now in its second year, AVBCC's GCRIS serves as a catalyst for advancing the future of cancer care by convening leading experts to explore breakthrough science, emerging therapies, and highlight innovations transforming cancer treatment worldwide. "The Global Cancer Research & Innovation Award is a reflection of AVBCC's commitment to celebrating the individuals and organizations driving progress across the oncology innovation ecosystem," says Burt Zweigenhaft, PhD, DLitt, Executive Director and Founder, AVBCC. "Dr. Vogt's extraordinary blend of scientific leadership, strategic vision, and unwavering commitment to advancing breakthrough therapies embodies the spirit of innovation and impact that this award was created to honor." "I am deeply honored to receive the inaugural Global Cancer Research & Innovation Award from the Association for Value-Based Cancer Care," says Dr. Vogt. "This recognition reflects the dedication of the entire Iovance team to make the promise of TIL therapy a reality for patients with advanced melanoma. The approval and launch of Amtagvi (R) underscored the potential for cell therapy to fundamentally change the treatment landscape for solid tumor cancers, and I'm grateful to the Association for championing innovation that ultimately benefits the patients who need it most." In 2024, Dr. Vogt led Iovance through one of the most significant milestones in modern oncology with the FDA approval and commercial launch of Amtagvi (R)(lifileucel), the first cell therapy ever approved for a solid tumor. This achievement opened an entirely new category of cancer treatment for patients with advanced melanoma and underscores the broader scientific and organizational progress he has championed. At Iovance's helm, Dr. Vogt has overseen the development of its end-to-end manufacturing infrastructure and commercial transformation including the acquisition and integration of Proleukin (R)- a decision that strengthened Iovance's ability to support the TIL therapy regimen. Additionally, he has spent more than 25 years advancing breakthrough cancer therapies across the industry, contributing to the approvals of Hycamtin (R), Votrient (R), Tafinlar (R), Mekinist (R), and Arzerra (R). With a rare dual background as both scientist and business leader, Dr. Vogt embodies the entrepreneurship, integrity, and patient centered commitment recognized by this award. About the Association for Value-Based Cancer Care (AVBCC) AVBCC is a 501(c)(6) educational organization dedicated to fostering the exchange of knowledge among stakeholders across the cancer care ecosystem who are responsible for ensuring that optimal care and access are delivered to all patients with cancer. Its goal is to inform, educate, and foster exchange of current and future state information between all stakeholders: Oncologists and Hematologists, Nurses, Oncology Nurse Navigators, Pathologists and Geneticists, Pharmacists, Practice Administrators, Practice Managers, Patient Advocacy Organizations, Managed Care Organizations, Insurance Companies, Third-Party Payers, Integrated Health Delivery Systems, Cancer Centers of Excellence, Medical Directors, Pharmacy Directors, Pharmaceutical and Biotech Manufacturers, Personalized Medicine Providers, Researchers, and, of course, cancer patients. Visit AVBCC.org to learn more about its organization and offerings. About Iovance Biotherapeutics Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi (R)(lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com. Amtagvi (R) and its accompanying design marks, Proleukin (R), Iovance (R), and IovanceCares(TM) are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Information on Iovance's broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Healthcare Industry Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Iovance Biotherapeutics became the top-performing mid-cap stock in the US market in Q3, with shares soaring 256%. The rally was driven by raised 2026 revenue guidance of $410 million to $420 million, representing 56% to 60% growth from 2025's $263 million. The company's optimism stems from strong demand for cancer treatments Amtagvi and Proleukin. In Q2, Iovance reported net revenues of $99 million, up 66% year-on-year, with $91 million from Amtagvi and $9 million from Proleukin. Amtagvi is the first FDA-approved individualised T-cell therapy for solid tumour cancer, specifically treating unresectable or metastatic melanoma. It has received regulatory approval in the US, Canada, and Australia. Analysts responded positively, with HC Wainwright raising its price target to $20 from $9 and Goldman Sachs assigning a $15 target.